GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000609122 | Liver | HCC | generation of precursor metabolites and energy | 340/7958 | 490/18723 | 4.04e-34 | 2.85e-31 | 340 |
GO:004603422 | Liver | HCC | ATP metabolic process | 198/7958 | 277/18723 | 8.30e-23 | 1.55e-20 | 198 |
GO:000911722 | Liver | HCC | nucleotide metabolic process | 300/7958 | 489/18723 | 1.61e-17 | 1.71e-15 | 300 |
GO:000675322 | Liver | HCC | nucleoside phosphate metabolic process | 304/7958 | 497/18723 | 1.78e-17 | 1.85e-15 | 304 |
GO:001969322 | Liver | HCC | ribose phosphate metabolic process | 248/7958 | 396/18723 | 3.15e-16 | 2.70e-14 | 248 |
GO:000925922 | Liver | HCC | ribonucleotide metabolic process | 240/7958 | 385/18723 | 2.07e-15 | 1.51e-13 | 240 |
GO:001605321 | Liver | HCC | organic acid biosynthetic process | 200/7958 | 316/18723 | 5.24e-14 | 3.22e-12 | 200 |
GO:003286821 | Liver | HCC | response to insulin | 172/7958 | 264/18723 | 7.14e-14 | 4.23e-12 | 172 |
GO:004639421 | Liver | HCC | carboxylic acid biosynthetic process | 198/7958 | 314/18723 | 1.19e-13 | 6.78e-12 | 198 |
GO:000915022 | Liver | HCC | purine ribonucleotide metabolic process | 226/7958 | 368/18723 | 1.36e-13 | 7.69e-12 | 226 |
GO:007252122 | Liver | HCC | purine-containing compound metabolic process | 250/7958 | 416/18723 | 2.26e-13 | 1.24e-11 | 250 |
GO:003286921 | Liver | HCC | cellular response to insulin stimulus | 137/7958 | 203/18723 | 4.69e-13 | 2.44e-11 | 137 |
GO:004343422 | Liver | HCC | response to peptide hormone | 247/7958 | 414/18723 | 9.55e-13 | 4.77e-11 | 247 |
GO:003166722 | Liver | HCC | response to nutrient levels | 276/7958 | 474/18723 | 2.30e-12 | 1.08e-10 | 276 |
GO:000616322 | Liver | HCC | purine nucleotide metabolic process | 236/7958 | 396/18723 | 3.59e-12 | 1.62e-10 | 236 |
GO:007137521 | Liver | HCC | cellular response to peptide hormone stimulus | 179/7958 | 290/18723 | 2.54e-11 | 9.88e-10 | 179 |
GO:190165321 | Liver | HCC | cellular response to peptide | 211/7958 | 359/18723 | 2.86e-10 | 9.63e-09 | 211 |
GO:000758421 | Liver | HCC | response to nutrient | 111/7958 | 174/18723 | 1.10e-08 | 2.73e-07 | 111 |
GO:000940811 | Liver | HCC | response to heat | 76/7958 | 110/18723 | 1.48e-08 | 3.58e-07 | 76 |
GO:000609022 | Liver | HCC | pyruvate metabolic process | 73/7958 | 106/18723 | 3.52e-08 | 7.82e-07 | 73 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PKLR | SNV | Missense_Mutation | | c.483G>C | p.Glu161Asp | p.E161D | P30613 | protein_coding | deleterious(0.02) | possibly_damaging(0.666) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PKLR | SNV | Missense_Mutation | | c.589N>A | p.Ala197Thr | p.A197T | P30613 | protein_coding | tolerated(0.47) | benign(0.02) | TCGA-BH-A0HY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | taxotere | CR |
PKLR | SNV | Missense_Mutation | novel | c.1401T>G | p.Cys467Trp | p.C467W | P30613 | protein_coding | tolerated(0.1) | probably_damaging(0.951) | TCGA-D8-A27F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
PKLR | SNV | Missense_Mutation | | c.1592G>A | p.Arg531His | p.R531H | P30613 | protein_coding | tolerated(0.29) | benign(0.003) | TCGA-E9-A22B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
PKLR | SNV | Missense_Mutation | novel | c.472A>C | p.Lys158Gln | p.K158Q | P30613 | protein_coding | deleterious(0.01) | possibly_damaging(0.579) | TCGA-E9-A5FK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | CR |
PKLR | insertion | Frame_Shift_Ins | novel | c.1029_1030insGGCGCCGCGGGCCAGCACACTGAGCAGCCCA | p.Ile344GlyfsTer67 | p.I344Gfs*67 | P30613 | protein_coding | | | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
PKLR | deletion | Frame_Shift_Del | novel | c.1475delC | p.Ala492GlufsTer38 | p.A492Efs*38 | P30613 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PKLR | SNV | Missense_Mutation | | c.373G>A | p.Glu125Lys | p.E125K | P30613 | protein_coding | deleterious(0.01) | possibly_damaging(0.481) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
PKLR | SNV | Missense_Mutation | | c.128N>C | p.Ser43Thr | p.S43T | P30613 | protein_coding | tolerated_low_confidence(0.19) | benign(0.003) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PKLR | SNV | Missense_Mutation | rs748700869 | c.1363N>G | p.Thr455Ala | p.T455A | P30613 | protein_coding | tolerated(0.31) | benign(0.006) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |